ESOC

ESOC 2023: AI tool outperforms human emergency call handlers in identifying stroke, new study shows

Retrieved on: 
Tuesday, May 23, 2023
Copenhagen University Hospital, Stroke, F1, Data, Patient, Risk, United States Secretary of Labor, Artificial intelligence, ESOC, AI, Death, Conference, Medical device, Pharmaceutical industry, EU

MUNICH, May 23, 2023 /PRNewswire/ -- Researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.

Key Points: 
  • MUNICH, May 23, 2023 /PRNewswire/ -- Researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.
  • The framework outperformed emergency call handlers in recognising stroke for both sexes and across all age groups studied, indicating its potential as a supplementary tool for early and precise stroke identification in the future.
  • The results, evaluated on calls from 2021, revealed that the AI framework performed more effectively than emergency call handlers in identifying stroke cases.
  • In contrast, emergency call handlers had a recall of 52.7% and precision of 17.1%, resulting in an F1 score of 25.8.

ESOC 2023: AI tool outperforms human emergency call handlers in identifying stroke, new study shows

Retrieved on: 
Tuesday, May 23, 2023
Copenhagen University Hospital, Stroke, F1, Data, Patient, Risk, United States Secretary of Labor, Artificial intelligence, ESOC, AI, Death, Conference, Medical device, Pharmaceutical industry, EU

MUNICH, May 23, 2023 /PRNewswire/ -- Researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.

Key Points: 
  • MUNICH, May 23, 2023 /PRNewswire/ -- Researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.
  • The framework outperformed emergency call handlers in recognising stroke for both sexes and across all age groups studied, indicating its potential as a supplementary tool for early and precise stroke identification in the future.
  • The results, evaluated on calls from 2021, revealed that the AI framework performed more effectively than emergency call handlers in identifying stroke cases.
  • In contrast, emergency call handlers had a recall of 52.7% and precision of 17.1%, resulting in an F1 score of 25.8.

Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Retrieved on: 
Monday, December 5, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Stroke, Document, Standard of care, CHMP, Intracerebral hemorrhage, Medicine, MAA, Mab, Agency, Centre de documentation de la musique contemporaine, EMA, Patient, Disability, Death, Infarction, ESOC, Regulatory affairs, ISIN, Biotechnology, Rankine scale, Committee, Particle-size distribution, GPVI, European Medicines Agency, Medication, AIS, PRIME, Clinical trial, Safety, A&B, Brain, Mortality, Marketing, VI, Thrombectomy, Committee for Medicinal Products for Human Use, Pharmaceutical industry, Medical imaging, INSERM

The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.

Key Points: 
  • The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.
  • Although CHMP recommendations were issued to further detail some analyses, the statistical methodology was therefore endorsed on its general principles.
  • In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Acticor Biotech or not currently considered material by Acticor Biotech.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

Retrieved on: 
Monday, September 26, 2022
Research, FDA, Neurology, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Newton, Safety, Microcirculation, Cuban Neuroscience Center, Patient, Clinical trial, Stroke, Research, Disease, National Institute, Intracranial hemorrhage, ISIN, Food, European Medicines Agency, GPVI, A&B, Breakthrough therapy, VI, Thrombectomy, Intracerebral hemorrhage, Mortality, EMA, FDA, Phase, ESOC, Incidence, Infarction, Brain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Standard of care, Mab, Medicine, Pharmaceutical industry, MD, INSERM

Chattanooga CHI Memorial is a state-of-the-art stroke unit that receives 1,400 stroke patients per year in unprecedented medical conditions, with a large part given to research. "

Key Points: 
  • Chattanooga CHI Memorial is a state-of-the-art stroke unit that receives 1,400 stroke patients per year in unprecedented medical conditions, with a large part given to research. "
  • ACTICOR had obtained an IND1 for this study from the U.S. Food and Drug Administration (FDA) in November 2021 and had initiated enrollment in Europe in the third quarter of 2021.
  • The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients.
  • In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke.

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Retrieved on: 
Thursday, July 21, 2022
Health, FDA, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Newton, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intracerebral hemorrhage, VI, Brain, Mab, Mortality, Medicine, Food, A&B, ISIN, National Institute, EMA, CMO, Safety, GPVI, Thrombectomy, Stroke, ESOC, Clinical trial, European Medicines Agency, FDA, Standard of care, Patient, Infarction, General manager, IND, Pharmaceutical industry, INSERM

ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Key Points: 
  • ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.
  • The "PRIME" status granted by the European Medicines Agency (EMA) allows to reinforce the support for the development of drugs that target an unmet medical need.
  • This status will allow Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.
  • Yannick Pletan, General Manager & CMO of Acticor Biotech, said: "We are delighted that the European Medicines Agency has granted "PRIME" status to glenzocimab.

Philips at ESOC 2022: showcasing integrated solutions across the stroke care pathway

Retrieved on: 
Tuesday, May 3, 2022
Radiology, Communication, MRS, Vall, AEX, Google Images, Solution, AI, Risk, Bleeding, MRI, Umbra, penumbra and antumbra, Gaps, Teaching hospital, NYSE, AF, Patient, Physician, CTP, Philips, Stroke, Ambulance, Research, Direct, Population, CTA, White matter, MCOT, ESOC, Workflow, Ultra, Cardiology, ILR, 3D, Time, Triage, CT, Data analysis, Diagnosis, Reperfusion, Disability, PHG, Conference, ECG, Pharmaceutical industry, Medical device, Medical imaging

With its suite of solutions, Philips is connecting information, technologies and people across the stroke care pathway, enabling care teams to work quickly and act decisively - a key factor in providing the best patient treatment.

Key Points: 
  • With its suite of solutions, Philips is connecting information, technologies and people across the stroke care pathway, enabling care teams to work quickly and act decisively - a key factor in providing the best patient treatment.
  • With our integrated suites, and by using validated AI and cloud technologies, we can facilitate collaborative care to optimize the stroke care pathway from diagnosis to treatment.
  • Philips comprehensive stroke suite includes solutions for stroke monitoring and communication in ambulances, tele-stroke patient assessment, diagnostic imaging and analysis, image-guided therapy, neurological monitoring and assessment, and more.
  • These solutions are aimed at improving diagnostic confidence, improving time to treatment, and helping reduce the risk of a second stroke.